Review article: safety of infliximab in clinical trials.
about
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective studyMolecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapiesDoes safety make a difference in selecting the right TNF antagonist?Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment.Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion.Therapy of systemic lupus erythematosus: a look into the futureUpdated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).Advances in the management of psoriasis: monoclonal antibody therapies.Biologic therapies for juvenile arthritisThe role of T cells in psoriasis.Clinical research helps elucidate the role of tumor necrosis factor-alpha in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes.Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Evolution of biologic therapies for the treatment of psoriasis.Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenReview article: The medical treatment of Crohn's perianal fistulas.Novel pharmacological approaches in the treatment of psoriasis.Drug safety in the treatment of Crohn's disease.Drug safety in Crohn's disease therapy.Hemorrhagic Pericardial Effusion with Tamponade: A Rare Adverse Effect of Infliximab-Case Report and Literature Review.Positioning biologic agents in the treatment of Crohn's disease.Biological therapies for rheumatoid arthritis: progress to date.Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease.Development of a mouse-feline chimeric antibody against feline tumor necrosis factor-alpha.Infliximab for the treatment of paediatric Crohn's disease: Obstacles to accessing a necessary therapy.Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis.Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate.Immunogenicity screening in protein drug development.
P2860
Q24798468-ECABCA00-367B-4838-B228-01B3B78C19AFQ33629320-5011946F-44FA-48F5-A788-DE6B96313C8BQ33708863-5E16DE10-4D0C-4818-8ADF-6AA8214374DDQ33966333-F2A4F32B-3626-46EC-B120-21EAC9EC03D8Q33997625-DCC27BD9-527B-4C7B-B287-E884CBB8B295Q34319316-1964F895-2AB7-4515-B966-D84FC5C0F578Q34454532-7516DF32-266A-478C-89C3-2B7101416F3FQ34560553-388B2252-5E3C-4897-93DA-B9D58225D42EQ34616587-41A5E769-E189-41B1-ADDC-848CC86D6990Q34731092-291A6F82-AEEF-43FB-BE6D-5FC30DD00E76Q34962946-2B39CEDC-6120-4A3F-9C7E-60F6831B2454Q35030921-56B0432A-80D5-4F43-A707-E8E4C7A11CBEQ35070925-018B6361-AA69-4198-8175-AF491581CB77Q35110104-E85A9376-1F4C-41DD-82D0-B4FDD89337CAQ35112336-1FA76D16-6AB4-47A7-87AE-5C2281EDEB1EQ35553451-5CF4F8F6-23D3-4E91-90C1-EB7E7696E708Q35579352-D69C2A1B-97F7-428A-B093-7CC0C0493B87Q35579517-E2ABA1DE-530F-41C4-83CB-B621A54413ADQ35606903-44B98B7E-6B8F-4FFF-A3DA-074DAEECD6ABQ35630063-87B180A5-9288-4112-AF80-F25EB1517308Q35758318-93951664-AB45-4D58-A71F-4B711AA0A3FEQ36008673-BF82A84C-4F52-4672-9606-B10CAA624D63Q36041692-2A31AC85-E361-4035-9A56-68BF4328F7EDQ37073426-20DDFBED-6C0D-4AEA-893A-36F47EE75F57Q37378365-B00D4C87-E29B-4F21-8053-587212D2D5DDQ37421884-3A67105A-ED09-4CDA-9A78-075B8143545FQ38096206-4DD3526F-4A06-4B77-B69C-359617132083Q40491745-A633F1C0-61FC-4E46-9682-8C67CD0B3829Q40644687-849835B0-F3DE-45DA-AEED-760817EE4DF7Q42032750-9B03A499-0CFE-499B-A163-F4573289B6ABQ44124071-0D85A8AB-2846-4500-98B1-1E01F49C7980Q47580545-EAD857E6-ACAD-4EE4-8AE6-170DD1F66873Q49168236-C241F6C2-6397-4EB6-BB53-0DD49B2A135A
P2860
Review article: safety of infliximab in clinical trials.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Review article: safety of infliximab in clinical trials.
@ast
Review article: safety of infliximab in clinical trials.
@en
type
label
Review article: safety of infliximab in clinical trials.
@ast
Review article: safety of infliximab in clinical trials.
@en
prefLabel
Review article: safety of infliximab in clinical trials.
@ast
Review article: safety of infliximab in clinical trials.
@en
P2860
P1476
Review article: safety of infliximab in clinical trials.
@en
P2093
Hanauer SB
P2860
P304
16-22; discussion 38
P356
10.1046/J.1365-2036.1999.00027.X
P407
P478
13 Suppl 4
P577
1999-09-01T00:00:00Z